Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine

David Taft, PhD, Tarang Vora, MS, Chen Ren, PhD, Patrick S. Zbyszewski, MBA, Joseph Morgan, MD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Manoj Maniar, PhD

Blood (2018) 132 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2018-99-118463

Published: 2018

Journal Articles

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

John Roboz, Shyamala C. Navada, MD, Sool Yeon Cho, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 1357.

https://doi.org/10.1182/blood-2018-99-115169

Published: 2018

Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 230.

https://doi.org/10.1182/blood-2018-99-119259

Published: 2018

Journal Articles

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials

Manoj Maniar, PhD, Chen Ren, PhD, Patrick S. Zbyszewski, MBA, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, David Taft, PhD

Blood (2018) 132 (Supplement 1): 3106.

https://doi.org/10.1182/blood-2018-99-116982

Published: 2018

Journal Articles

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Azra Raza, MD, Aref Al-Kali, MD, Raoul Tibes, MD PhD, Gary Spitzer, MD, Manila Gaddh, MD, Benjamin Tycko, MD PhD, Sangmin Lee, MD, Naomi Galili, PhD, Abdullah Mahmood Ali, PhD, John G. Mears, MD, Siddhartha Mukherjee, MD PhD, Ryan Shelton, BS, Steven M. Fruchtman, MD, Michael E. Petrone, MD MPH, Patrick S. Zbyszewski, MBA, Mark Lawrence Heaney, MD PhD

Blood (2017) 130 (Supplement 1): 1689.

https://doi.org/10.1182/blood.V130.Suppl_1.1689.1689

Published: 2017

Journal Articles

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Pierre Fenaux, MD PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 3167.

https://doi.org/10.1182/blood.V128.22.3167.3167

Published: 2016

Journal Articles

A Genomic Predictive Signature for Rigosertib in Lower Risk MDS Derived By Integrating Clinical Response, Mechanism of Action Data and Simulation

Steven M. Fruchtman, MD, Abdullah Mahmood Ali, PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Benjamin Hoffman, PhD, Shireen Vali, PhD, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Azra Raza, MD

Blood (2016) 128 (22): 5535.

https://doi.org/10.1182/blood.V128.22.5535.5535

Published: 2016

Journal Articles

Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, MD, Pierre Fenaux, MD PhD, Aref Al-Kali, MD, Shyamala C. Navada, MD, Maria R. Baer, MD, Azra Raza, MD, Peter Greenberg, MD, Karl-Anton Kreuzer, MD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Gail J. Roboz, Valeria Santini, MD, Uwe Platzbecker, MD, Michael E. Petrone, MD MPH, Bernard Brownstein, MD, Patrick Simon Zbyszewski, MBA, Manoj Maniar, PhD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 2011.

https://doi.org/10.1182/blood.V128.22.2011.2011

Published: 2016

Journal Articles

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

Guillermo Garcia-Manero, MD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Bernard Brownstein, MD, Hannes Loferer, PhD, Nozar Azarnia, PhD, Shireen Vali, PhD, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Lewis R. Silverman, MD

Blood (2016) 128 (22): 4324.

https://doi.org/10.1182/blood.V128.22.4324.4324

Published: 2016

Journal Articles

Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

Ghulam J Mufti, FRCP, FRCPath, MD, Lewis R. Silverman, MD, Steven Best, PhD, Steve Fructman, MD, Nozar Azarnia, PhD, Michael E. Petrone, MD MPH, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 5257.

https://doi.org/10.1182/blood.V126.23.5257.5257

Published: 2015

Journal Articles

Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Christopher R. Cogle, MD, Sudipto Mukherjee, MD MPH, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Rita Percy, Michael E. Petrone, MD MPH, Scott Megaffin, Ayanna M Anene, BS, Jesse Ortendahl, MS, Dorothy Romanus, RPh, PhD, Tanya GK Bentley, PhD

Blood (2014) 124 (21): 1928.

https://doi.org/10.1182/blood.V124.21.1928.1928

Published: 2014

Journal Articles

Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1 st -Line Therapy

Christopher R. Cogle, MD, Sudipto Mukherjee, MD MPH, Tanya GK Bentley, PhD, Michael S Broder, MD MSHS, Eunice Chang, PhD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH, Gordon H Sun, MD MS

Blood (2014) 124 (21): 2627.

https://doi.org/10.1182/blood.V124.21.2627.2627

Published: 2014

Journal Articles

Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1 st -Line Therapy, Discontinuation and the Need of Additional Therapies

Sudipto Mukherjee, MD MPH, Christopher R. Cogle, MD, Tanya GK Bentley, PhD, Michael S Broder, MD MSHS, Eunice Chang, PhD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH, Gordon H Sun, MD MS

Blood (2014) 124 (21): 2598.

https://doi.org/10.1182/blood.V124.21.2598.2598

Published: 2014

Journal Articles

Incidence of First-Line and Second-Line Myelodysplastic Syndrome in a US Commercial Claims Database

Christopher R. Cogle, MD, Sandra E. Kurtin, RN, MS, AOCN, ANP-C, Tanya GK Bentley, PhD, Michael S Broder, MD MSHS, Eunice Chang, PhD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH, Gordon H Sun, MD MS

Blood (2014) 124 (21): 6008.

https://doi.org/10.1182/blood.V124.21.6008.6008

Published: 2014

Journal Articles

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Erin P. Demakos, RN, CCRN, Lewis R. Silverman, MD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH

Blood (2014) 124 (21): 1287.

https://doi.org/10.1182/blood.V124.21.1287.1287

Published: 2014

NARROW

Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

A Genomic Predictive Signature for Rigosertib in Lower Risk MDS Derived By Integrating Clinical Response, Mechanism of Action Data and Simulation

Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1 st -Line Therapy

Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1 st -Line Therapy, Discontinuation and the Need of Additional Therapies

Incidence of First-Line and Second-Line Myelodysplastic Syndrome in a US Commercial Claims Database

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only